1
|
Castagna L, Bramanti S, Devillier R, Pagliardini T, Sarina B, Lemarie C, Furst S, Mariotti J, Granata A, de Philippis C, Harbi S, Legrand F, Maisano V, Bouabdallah R, Carlo-Stella C, Calmels B, Chabannon C, Blaise D, Santoro A. IMPACT OF CLASS II HLA MISMATCH ON CLINICAL OUTCOMES IN HODGKIN LYMPHOMA PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANTATION (HAPLO-SCT) WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY). Hematol Oncol 2019. [DOI: 10.1002/hon.109_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L. Castagna
- Hematology; Humanitas Research Center; Rozzano Italy
| | - S. Bramanti
- Hematology; Humanitas Research Center; Rozzano Italy
| | - R. Devillier
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - B. Sarina
- Hematology; Humanitas Research Center; Rozzano Italy
| | - C. Lemarie
- Hematology; Institut Paoli Calmettes; Marseille France
| | - S. Furst
- Hematology; Institut Paoli Calmettes; Marseille France
| | - J. Mariotti
- Hematology; Humanitas Research Center; Rozzano Italy
| | - A. Granata
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - S. Harbi
- Hematology; Institut Paoli Calmettes; Marseille France
| | - F. Legrand
- Hematology; Institut Paoli Calmettes; Marseille France
| | - V. Maisano
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | | | - B. Calmels
- Hematology; Institut Paoli Calmettes; Marseille France
| | - C. Chabannon
- Hematology; Institut Paoli Calmettes; Marseille France
| | - D. Blaise
- Hematology; Institut Paoli Calmettes; Marseille France
| | - A. Santoro
- Hematology; Humanitas Research Center; Rozzano Italy
| |
Collapse
|
2
|
de Philippis C, Legrande F, Bramanti S, Montes de Oca C, Dulery R, Bouabdallah R, Granada A, Devillier R, Mariotti J, Sarina B, Harbi S, Maisano V, Furst S, Pagliardini T, Weiller P, Lemarie C, Calmels B, Chabannon C, Carlo-Stella C, Santoro A, Mohty M, Blaise D, Castagna L. CHECKPOINT INHIBITION BEFORE HAPLOIDENTICAL TRANSPLANTATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA PATIENTS IS ASSOCIATED WITH HIGHER PFS WITHOUT INCREASED TOXICITIES. Hematol Oncol 2019. [DOI: 10.1002/hon.107_2630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - F. Legrande
- Hematology; Institut Paoli Calmettes; Marseille France
| | - S. Bramanti
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | | | - R. Dulery
- Hematology; Hospital Saint-Antoine; Paris France
| | | | - A. Granada
- Hematology; Institut Paoli Calmettes; Marseille France
| | - R. Devillier
- Hematology; Institut Paoli Calmettes; Marseille France
| | - J. Mariotti
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | - B. Sarina
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | - S. Harbi
- Hematology; Institut Paoli Calmettes; Marseille France
| | - V. Maisano
- Hematology; Institut Paoli Calmettes; Marseille France
| | - S. Furst
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - P.J. Weiller
- Hematology; Institut Paoli Calmettes; Marseille France
| | - C. Lemarie
- Hematology; Institut Paoli Calmettes; Marseille France
| | - B. Calmels
- Hematology; Institut Paoli Calmettes; Marseille France
| | - C. Chabannon
- Hematology; Institut Paoli Calmettes; Marseille France
| | | | - A. Santoro
- Hematology; Humanitas Cancer Center; Rozzano Italy
| | - M. Mohty
- Hematology; Hospital Saint-Antoine; Paris France
| | - D. Blaise
- Hematology; Institut Paoli Calmettes; Marseille France
| | - L. Castagna
- Hematology; Humanitas Cancer Center; Rozzano Italy
| |
Collapse
|
3
|
AL-Yami H, AL-osail E, Harbi S, Bubshait M. Benign osseous metaplasia of the breast: Case report. Int J Surg 2018. [DOI: 10.1016/j.ijsu.2018.05.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
4
|
Legrand F, Le Floch AC, Granata A, Fürst S, Faucher C, Lemarie C, Harbi S, Bramanti S, Calmels B, El-Cheikh J, Chabannon C, Weiller PJ, Vey N, Castagna L, Blaise D, Devillier R. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. Bone Marrow Transplant 2016; 52:620-621. [PMID: 27941765 DOI: 10.1038/bmt.2016.326] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F Legrand
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - A-C Le Floch
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - A Granata
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - S Fürst
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - C Faucher
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - C Lemarie
- Cell therapy facility, Institut Paoli-Calmettes, Marseille, France.,CIC biothérapies: Inserm CBT-1409, Marseille, France
| | - S Harbi
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France
| | - S Bramanti
- Departement of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - B Calmels
- Cell therapy facility, Institut Paoli-Calmettes, Marseille, France.,CIC biothérapies: Inserm CBT-1409, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, Institut Paoli-Calmettes, Marseille, France
| | - J El-Cheikh
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.,Bone marrow transplantation program, American University of Beirut, Beirut, Lebanon
| | - C Chabannon
- Cell therapy facility, Institut Paoli-Calmettes, Marseille, France.,CIC biothérapies: Inserm CBT-1409, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, Institut Paoli-Calmettes, Marseille, France.,Aix-Marseille Université UM 105, Marseille, France
| | - P-J Weiller
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.,Aix-Marseille Université UM 105, Marseille, France
| | - N Vey
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, Institut Paoli-Calmettes, Marseille, France.,Aix-Marseille Université UM 105, Marseille, France.,CNRS UMR 7258, Marseille, France
| | - L Castagna
- Bone marrow transplantation program, American University of Beirut, Beirut, Lebanon
| | - D Blaise
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, Institut Paoli-Calmettes, Marseille, France.,Aix-Marseille Université UM 105, Marseille, France.,CNRS UMR 7258, Marseille, France
| | - R Devillier
- Department of Hematology, Institut Paoli-Calmettes, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, U1068, Institut Paoli-Calmettes, Marseille, France.,Aix-Marseille Université UM 105, Marseille, France.,CNRS UMR 7258, Marseille, France
| |
Collapse
|
5
|
Castagna L, Sarina B, Crocchiolo R, Bramanti S, Furst S, Devillier R, Coso D, Bouabdallah R, Mokart D, Morabito L, Harbi S, Giordano L, Rimondo A, Jean Weiller P, Carlo-Stella C, Santoro A, Chabannon C, Blaise D. Outcomes of Hodgkin lymphoma patients who relapse after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51:1644-1646. [PMID: 27748737 DOI: 10.1038/bmt.2016.257] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- L Castagna
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - B Sarina
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Crocchiolo
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Bramanti
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Furst
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Devillier
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - D Coso
- Hematology Department, Lymphoma Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - R Bouabdallah
- Hematology Department, Lymphoma Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - D Mokart
- Intensive Care Unit, Institut Paoli Calmettes, Marseille, France
| | - L Morabito
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - S Harbi
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - L Giordano
- Biostatistical Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - A Rimondo
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - P Jean Weiller
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy
| | - C Carlo-Stella
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
| | - A Santoro
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Humanitas University, Rozzano, Italy
| | - C Chabannon
- Cell Therapy Unit, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
| | - D Blaise
- Hematology Department, Transplantation Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Hematology Department, Lymphoma Program, Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille, Inserm, Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
| |
Collapse
|
6
|
Crocchiolo R, Castagna L, Furst S, Devillier R, Sarina B, Bramanti S, El-Cheikh J, Granata A, Harbi S, Morabito L, Faucher C, Rimondo A, Girardi D, Mohty B, Calmels B, Carlo-Stella C, Chabannon C, Bouabdallah R, Santoro A, Vey N, Weiller PJ, Blaise D. The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide. Bone Marrow Transplant 2016; 51:1134-6. [DOI: 10.1038/bmt.2016.69] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
7
|
Castagna L, Bramanti S, Furst S, Giordano L, Sarina B, Crocchiolo R, El-Cheikh J, Cheikh JE, Granata A, Morabito L, Mauro E, Faucher C, Mohty B, Harbi S, Devillier R, Chabannon C, Carlo-Stella C, Santoro A, Blaise D. Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide. Bone Marrow Transplant 2015; 51:462-5. [PMID: 26595078 DOI: 10.1038/bmt.2015.289] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- L Castagna
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - S Bramanti
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - S Furst
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - L Giordano
- Statistic Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - B Sarina
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - R Crocchiolo
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | | | - J El Cheikh
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - A Granata
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - L Morabito
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - E Mauro
- Department of Hematology, Ospedale Ferrarotto, Catania, Italy
| | - C Faucher
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - B Mohty
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - S Harbi
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - R Devillier
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France
| | - C Chabannon
- Cell Therapy Unit Institut Paoli Calmettes, Marseille, France.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
| | - C Carlo-Stella
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - A Santoro
- Department of Hematology, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
| | - D Blaise
- Department of Hematology, Transplantation Program Institut Paoli Calmettes, Marseille, France.,Aix-Marseille Université, Marseille, France.,Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
| |
Collapse
|
8
|
Devillier R, Bramanti S, Fürst S, Sarina B, El-Cheikh J, Crocchiolo R, Granata A, Chabannon C, Morabito L, Harbi S, Faucher C, Santoro A, Weiller PJ, Vey N, Carlo-Stella C, Castagna L, Blaise D. T-replete haploidentical allogeneic transplantation using post-transplantation cyclophosphamide in advanced AML and myelodysplastic syndromes. Bone Marrow Transplant 2015; 51:194-8. [PMID: 26551778 DOI: 10.1038/bmt.2015.270] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Revised: 09/24/2015] [Accepted: 09/29/2015] [Indexed: 11/12/2022]
Abstract
Unmanipulated haploidentical transplantation (Haplo-SCT) using post-transplantation cyclophosphamide (PT-Cy) represents an alternative for patients with high-risk diseases lacking HLA-identical donor. Although it provides low incidences of GVHD, the efficacy of Haplo-SCT is still questioned, especially for patients with myeloid malignancies. Thus, we analyzed 60 consecutive patients with refractory (n=30) or high-risk CR (n=30) AML or myelodysplastic syndromes (MDSs) who underwent PT-Cy Haplo-SCT. The median age was 57 years (22-73 years), hematopoietic cell transplantation comorbidity index was ⩾3 in 38 patients (63%) and Haplo-SCT was the second allogeneic transplantation for 10 patients (17%). Although most of patients received PBSC as graft source (n=48, 80%), we found low incidences of grade 3-4 acute (2%) and severe chronic GVHD (4%). Among patients with high-risk CR diseases, 1-year non-relapse mortality, cumulative incidence of relapse, progression-free and overall survivals were 20%, 32%, 47% and 62%, respectively. In patients with refractory disease, corresponding results were 34%, 35%, 32% and 37%, respectively. We conclude that PT-Cy Haplo-SCT could provide promising anti-leukemic effect even in the setting of very advanced diseases. Thus, it represents a viable alternative for high-risk AML/MDS patients without HLA-identical donor.
Collapse
Affiliation(s)
- R Devillier
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| | - S Bramanti
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - S Fürst
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - B Sarina
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - J El-Cheikh
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - R Crocchiolo
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - A Granata
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - C Chabannon
- Aix-Marseille University, Medicine Faculty, Marseille, France.,Cell Therapy Facility, Institut Paoli Calmettes, Marseille, France
| | - L Morabito
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - S Harbi
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - C Faucher
- Department of Hematology, Institut Paoli Calmettes, Marseille, France
| | - A Santoro
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - P-J Weiller
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| | - N Vey
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| | - C Carlo-Stella
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - L Castagna
- Department of Hematology, Humanitas Cancer Center, Rozzano, Italy
| | - D Blaise
- Department of Hematology, Institut Paoli Calmettes, Marseille, France.,Aix-Marseille University, Medicine Faculty, Marseille, France
| |
Collapse
|
9
|
Harrell MD, Harbi S, Hoffman JF, Zavadil J, Coetzee WA. Large-scale analysis of ion channel gene expression in the mouse heart during perinatal development. Physiol Genomics 2006; 28:273-83. [PMID: 16985003 DOI: 10.1152/physiolgenomics.00163.2006] [Citation(s) in RCA: 79] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The immature and mature heart differ from each other in terms of excitability, action potential properties, contractility, and relaxation. This includes upregulation of repolarizing K(+) currents, an enhanced inward rectifier K(+) (Kir) current, and changes in Ca(2+), Na(+), and Cl(-) currents. At the molecular level, the developmental regulation of ion channels is scantily described. Using a large-scale real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) assay, we performed a comprehensive analysis of ion channel transcript expression during perinatal development in the embryonic (embryonic day 17.5), neonatal (postnatal days 1-2), and adult Swiss-Webster mouse hearts. These data are compared with publicly available microarray data sets (Cardiogenomics project). Developmental mRNA expression for several transcripts was consistent with the published literature. For example, transcripts such as Kir2.1, Kir3.1, Nav1.5, Cav1.2, etc. were upregulated after birth, whereas others [e.g., Ca(2+)-activated K(+) (KCa)2.3 and minK] were downregulated. Cl(-) channel transcripts were expressed at higher levels in immature heart, particularly those that are activated by intracellular Ca(2+). Defining alterations in the ion channel transcriptome during perinatal development will lead to a much improved understanding of the electrophysiological alterations occurring in the heart after birth. Our study may have important repercussions in understanding the mechanisms and consequences of electrophysiological alterations in infants and may pave the way for better understanding of clinically relevant events such as congenital abnormalities, cardiomyopathies, heart failure, arrhythmias, cardiac drug therapy, and the sudden infant death syndrome.
Collapse
Affiliation(s)
- M D Harrell
- Pediatric Cardiology, New York University School of Medicine, New York, New York 10016, USA
| | | | | | | | | |
Collapse
|
10
|
Kouretas P, Ross M, Reitz B, Robbins R, Shumway N, Harbi S, Miller J, Gamberg P, Chin C, Bernstein D. 10 and 20-year long-term survival after pediatric orthotopic heart transplantation. J Heart Lung Transplant 2004. [DOI: 10.1016/j.healun.2003.11.053] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|